Safety and Efficacy of ALC in Breast Cancer in Subjects With Fatigue



Status:Terminated
Conditions:Breast Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:10/14/2017
Start Date:March 2007
End Date:September 2008

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Safety and Efficacy of Oral Acetyl-l-carnitine (ALC) in Non-anemic Potentially Curable Breast Cancer Subjects Undergoing Adjuvant Radiation Therapy Who Have Moderate to Severe Fatigue

The objective of this study is to evaluate the efficacy and safety of ALC in the treatment of
non-anemic, breast cancer subjects who develop moderate or severe fatigue during adjuvant
radiotherapy.

The objective of this study is to evaluate the efficacy and safety of ALC in the treatment of
non-anemic, breast cancer subjects who develop moderate or severe fatigue during adjuvant
radiotherapy

Inclusion Criteria:

- Stage 0-III breast cancer in which adjuvant radiation is indicated;

- Qualifying Brief Fatigue Inventory (BFI) score 6. -

Exclusion Criteria:

- Medication to treat or manage fatigue and pain

- Use of erythropoietin to control anemia

- Clinical evidence of hypothyroidism or hyperthyroidism
We found this trial at
1
site
University of Texas M.D. Anderson Cancer Center
1515 Holcombe Blvd
Houston, Texas 77030
 713-792-2121
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
?
mi
from
Houston, TX
Click here to add this to my saved trials